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Abstract
Background: Several guidelines state that postoperative adjuvant chemotherapy (AC) confers survival benefits to
patients with lymph node-positive colorectal cancer. However, older patients are usually not administered AC due
to the higher risk of side effects. The aim of this study was to evaluate the benefit of AC for elderly patients (EP)
and examine its tolerability.
Methods: Data from 204 patients with lymph node-positive colon cancer were retrospectively analyzed. Patients
were subdivided into two groups: EP, >75 years old (n = 53) and young patients (YP), <75 years old (n = 151).
Clinicopathological features, type of chemotherapy, and outcomes were compared between groups.
Results: Frequency of comorbidities and performance status were significantly higher in EP (p < 0.01 each), a
greater proportion of YP (76 %) than EP received AC (40 %, p < 0.01), and YP received combination therapy more
frequently than EP (p < 0.01). In terms of side effects, few EP showed severe side effects. Both YP and EP gained
survival benefits from AC (p = 0.07 and p < 0.01, respectively).
Conclusions: AC should not be withheld from eligible EP purely because of age.
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Background
Colorectal cancer is one of the most common cancers
worldwide, with an incidence of 1.2 million per year glo-
bally [1]. Generally, as the population ages, the incidence
of elderly colorectal cancer patients is likely to increase.
According to the tumor-node-metastasis system, colo-
rectal cancer with lymph node metastasis is defined as
stage III disease [2]. About 50 % of patients with stage
III cancer reportedly experience disease recurrence, such
as local recurrence or distant metastasis, and the 5-year
survival rate is 68–77 % [3, 4]. In the 1990s, the concept
of adjuvant chemotherapy (AC) after curative resection
for patients with stage III colon cancer was established
to improve long-term outcomes [5]. AC can reportedly
result in a 30 % decrease in relapse rates compared with
surgery alone. Furthermore, several randomized con-
trolled studies have revealed that stage III colon cancer
patients benefit in terms of both relapse-free survival
and overall survival using combination therapies that in-
clude oxaliplatin [6, 7].
However, not all patients with stage III colon cancer re-
ceive postoperative AC, with such treatment withheld
from 48 to 77 % of colon cancer cases [8–10]. In general,
elderly patients (EP) display higher rates of comorbidities,
including cardiovascular disease, diabetes mellitus, and
pulmonary disease, than younger patients (YP) [11–13].
As EP may experience a higher rate of side effects com-
pared to YP, the decision to start postoperative AC for EP
should be made carefully [9]. The Adjuvant Colon Cancer
End Points (ACCENT) group assembled patient data from
18 trials testing fluoropyrimidine-based AC for patients
with stage II or III colorectal cancer. Previous analyses of
data from ACCENTcomparing surgery alone with surgery
followed by fluorouracil-based AC have revealed that
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patients ≥70 years old experienced similar benefits from
AC compared with YP [14, 15]. However, another study
revealed that EP seemed to gain reduced benefit from the
addition of oxaliplatin to fluoropyrimidine in the adjuvant
setting.
The aim of this study was to evaluate the effectiveness
of AC for EP with colorectal cancer. We also examined




The institutional review board approved this retrospect-
ive observational study. Informed consent was obtained
from all patients prior to surgery.
From January 2005 to December 2014, a total of 790
colorectal cancer patients underwent colorectal resec-
tion of the primary cancer in the Department of Surgi-
cal Oncology at Nagasaki University Graduate School
of Biological Sciences. Among these, 215 patients were
diagnosed with lymph node-positive colon cancer based
on histopathological examination. Although neoadju-
vant chemotherapy (NAC) is usually administered to
patients with locally advanced colorectal cancer, the
present study excluded 11 patients who received NAC
to avoid confounding effects on AC. As a result, data
were obtained for a final total of 204 patients with
lymph node-positive colon cancer. These patients were
subdivided into two groups: EP, ≥75 years old (n = 53)
and YP, <75 years old (n = 151).
Before surgery, the appropriateness of resection was
determined by abdominal CT and colonoscopy. The fol-
lowing data were retrospectively collected: age, sex, per-
formance status, tumor markers including CEA and
CA19-9, International Union Against Cancer tumor
stage, operation time, blood loss, and postoperative data
(including pathology, lymphatic and vessel invasion,
depth of tumor invasion, hospital stay, and 30-day mor-
bidity and mortality rates). Postoperative complications
were graded according to the Clavien-Dindo classifica-
tion categorizing surgical complications from grades 1 to
5, based on the invasiveness of the treatment required.
In the present study, complications were defined as con-
ditions that required treatment (Clavien-Dindo classifi-
cation grades 2–5).
Colectomy, anterior resection, and abdominoperineal
resection plus lymph node resection were performed ac-
cording to the guidelines of the Japanese Society for
Cancer of the Colon and Rectum. Either hand-sewn
anastomosis or end-to-end anastomosis using a double-
stapling technique was performed, depending on tumor
location. Mortality and morbidity data were collected
from the databases of our department and collaborating
hospitals.
AC
AC was started within 4–8 weeks after surgery, using 5-
fluorouracil, TS-1, or capecitabine as a single-agent chemo-
therapy or oxaliplatin, 5-fluorouracil, and folinic acid
(FOLFOX), S-1 and oxaliplatin (SOX), or capecitabine and
oxaliplatin (XELOX) as a combination therapy. The side
effects were graded according to Common Terminology
Criteria for Adverse Events version 4.0.
Statistical analysis
Data from the different groups were compared using
Student’s t test. Continuous data are expressed as mean
± standard deviation (SD). On univariate analysis, com-
parisons of categorical variables were performed using
the chi-square test or Fisher’s exact test. Values of p <
0.05 were considered significant. Overall and disease-
free survival rates were calculated according to Kaplan-
Meier methods. Differences between groups were tested
for significance using the log-rank test. All statistical
analyses were performed using SPSS version 22 software
(SPSS, Chicago, IL).
Results
Clinicopathological features and parameters
Table 1 shows the characteristics of each group. Sex,
age, body mass index, tumor location, tumor type, tumor
size, lymph node metastasis, and concentrations of
tumor markers, including CEA and CA19-9, did not dif-
fer significantly between groups. Frequency of comorbid-
ities and performance status were significantly higher in
EP than in YP (p < 0.01 each). A number of patients who
had hypertension, cardiac disease, or brain infarction
were identified among EP.
Surgical features and outcomes
Lymphatic invasion was significantly more frequent in
EP than in YP (p = 0.02). No significant differences in
histological type, vessel invasion, operation time, blood
loss, operative procedures, or combined resection were
seen between groups. Postoperative complications and
length of hospital stay likewise did not differ between
groups. Among YP, 76 % (115/151) had received AC,
compared to only 40 % (21/52) among EP (p < 0.01;
Table 2).
Types of AC
Among YP who received AC, 62 % (71/115) received
single-agent chemotherapy (TS-1, n = 29; tegafur-uracil,
n = 33; capecitabine, n = 9) and 38 % (44/115) received
combination therapy (FOLFOX, n = 19; SOX, n = 14;
XELOX, n = 11). On the other hand, among EP, 71 %
(15/21) were administered single-agent chemotherapy
(TS-1, n = 3; tegafur-uracil, n = 11; capecitabine, n = 1)
and only 29 % (6/21) received combination therapy
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(FOLFOX, n = 4; SOX, n = 1; XELOX, n = 1). Significant
differences were evident between groups in the selection
of chemotherapeutic agents (p < 0.01) (Table 3).
Tolerability of chemotherapy
Thirteen of the 71 YP (18.3 %) who received single-
agent chemotherapy experienced side effects of grade 3
or greater, compared to 19 of 44 YP patients (43.2 %)
who received combination therapy (median follow-up
period, 35 vs. 51 months, respectively). On the other
hand, none of the EP who received single-agent chemo-
therapy experienced severe side effects (0 %), compared
to EP (33.3 %) who received combination therapy. In
both groups, neutropenia was the most frequent side ef-
fect in this study. In YP, AC with single/combination
agents was discontinued in eight of 71 patients (11.3 %)
Table 1 Relationship between patient age and clinicopathological features
Age <75 years Age ≥75 years p
n 151 53
Age, years 61 (30–74) 81 (75–94)
Sex (male/female) 85 (56.3 %)/66 (43.7 %) 24 (45.3 %)/29 (54.7 %) 0.16
Body mass index (kg/m2) 23.3 23.5 0.91
Co-morbidity (no/yes) 91 (60.3 %)/60 (39.7 %) 18 (40.0 %)/35 (60.0 %) <0.01
Hypertension 20 13
Diabetes mellitus 12 3
Respiratory disease 6 3
Heart disease 6 6
Renal disease 5 3
Brain infarction 5 4
Connective tissue disease 3 2
Liver disease 3 1
Performance status (0, 1/2, 3) 137 (90.7 %)/14 (9.3 %) 38 (71.7 %)/15 (28.3 %) <0.01
Location (C/A/T/D/S/R) 8 (5.3 %)/18 (11.9 %)/10 (6.6 %)/8 (5.3 %)/34 (22.5 %)/73
(48.4 %)
4 (7.5 %)/12 (22.6 %)/5 (9.4 %)/3 (5.7 %)/12 (22.6 %)/17
(32.2 %)
0.28
Tumor type (0/1/2/3/4/5) 17 (11.3 %)/25 (16.6 %)/94 (62.2 %)/13 (8.7 %)/1 (0.6 %)/
1 (0.6 %)
1 (1.9 %)/7 (13.2 %)/38 (71.7 %)/6 (11.3 %)/0/1 (1.9 %) 0.26
Tumor size (mm) 69 (9–103) 47 (9–87) 0.36
Tumor depth
(m/sm/mp/ss/se/ai)
0/2 (1.3 %)/19 (12.6 %)/108 (71.5 %)/12 (7.9 %)/10
(6.7 %)
0/2 (3.8 %)/4 (7.5 %)/37 (69.8 %)/7 (13.2 %)/3 (5.7 %) 0.74
Lymph node metastasis
(N1/2/3)
98 (64.9 %)/38 (25.2 %)/15 (9.9 %) 34 (64.2 %)/13 (24.5 %)/6 (11.3 %) 0.95
CEA 8.1 9.1 0.69
CA19-9 26.1 21.4 0.97
Table 2 Relationship between tumor and surgical features and outcomes
Age <75 years Age ≥75 years p
Histological grade (well/mod/poor) 54 (35.8 %)/83 (55.0 %)/14 (9.2 %) 19 (35.8 %)/28 (52.8 %)/6 (11.4 %) 0.99
Lymphatic invasion (no/yes) 6 (4.0 %)/145 (96.0 %) 6 (11.3 %)/47 (88.7 %) 0.02
Vessel invasion (no/yes) 20 (13.2 %)/131 (86.8 %) 7 (13.2 %)/46 (86.8 %) 0.99
Operation time (min) 480 (80–713) 241 (74–645) 0.35
Blood loss (g) 185 (10–1400) 129 (20–510) 0.07
Laparoscopic surgery (no/yes) 83 (55.0 %)/69 (45.0 %) 31 (58.5 %)/22 (41.5 %) 0.62
Composite resection (no/yes) 143 (94.7 %)/8 (5.3 %) 48 (90.6 %)/5 (9.4 %) 0.38
Postoperative chemotherapy (no/yes) 36 (23.8 %)/115 (76.2 %) 32 (60.4 %)/21 (39.6 %) <0.01
Postoperative complication (no/yes) 95 (62.9 %)/56 (37.1 %) 32 (60.4 %)/21 (39.6 %) 0.74
Hospital stay (days) 25.7 (14–31) 25.5 (16–40) 0.93
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and six of 44 patients (13.6 %), respectively. On the
other hand, in EP, AC with single/combination agents
was discontinued in one of 15 patients (6.7 %) and none
of six patients (0 %) (Table 4). During the observation
period, one patient in the YP group who received
mFOLFOX6 died due to acute pneumonia.
Kaplan-Meier curves of the effect of chemotherapy on
disease-free and overall survival
YP showed no significant differences in disease-free sur-
vival between chemotherapy and non-chemotherapy
subgroups (p = 0.35), and while overall survival tended
to be better in the chemotherapy subgroup, the effect
was still not significant (p = 0.07) (Fig. 1a). Likewise in
EP, no significant difference in disease-free survival was
evident between chemotherapy subgroups (p = 0.47).
However, overall survival was significantly better in the
chemotherapy subgroup (p = 0.01) (Fig. 1b).
Discussion
Although the proportion of patients receiving AC was
much lower among EP than among YP, the present re-
sults suggest that postoperative AC might be effective
for improving overall survival in EP. In addition, the en-
tire course of AC was able to be completed in many EP
without severe side effects.
Previous studies have revealed the survival benefits of
postoperative AC for patients with stage III colorectal
cancer [16–18]. However, emphasis has been placed on
careful diligence in assessing the indications for AC in
EP, since these patients often show low performance sta-
tus, major organ dysfunction, and high frequencies of
comorbidities [19, 20]. In the present study, the fre-
quency of comorbidities was higher and performance
status was lower in EP than in YP (p < 0.01 each).
In the 1990s, the rate of administering AC was report-
edly lower in EP (10–32 %) than in YP (55–77 %) [9,
10]. Ko and colleagues recently examined data from 810
colorectal cancer patients with lymph node metastasis
[1]. They revealed that AC tended to be administered
less frequently to EP (57 %) than to YP (91 %), as previ-
ously reported, even though the benefits of AC have
been widely recognized. Furthermore, combination ther-
apy was selected less often for EP (32 %) than for YP
(74 %). In our study, the proportion of patients receiving
AC was lower among EP (21/52, 40 %) than among YP
(115/151, 76 %). In addition, the frequency of adminis-
tering combination therapy was significantly lower in EP
(28.6 %) than in YP (38.2 %, p < 0.01). The most com-
mon reason for withholding AC from EP was identified
as patient age (15/32; 47 %) (Additional file 1: Table S1).
In the YP group, AC was most often withheld from pa-
tients due to patient choice (15/36; 42 %). Such findings
are supported by the results of a previous report on rea-
sons for withholding AC [21].
Some studies have revealed that EP are at increased
risk of developing side effects, such as nausea, stomatitis,
vomiting, and neutropenia [9, 22–25]. However, other
investigations have indicated that the rate of side effects
does not differ between EP and YP [26, 27]. In a ran-
domized trial involving 1014 patients, incidences of neu-
tropenia, gastrointestinal toxic effects, and dermatitis
were not significantly different between different age
groups [28]. In our study, the rate of AC completion was
high in the EP group, and the incidence of side effects of
grade 3 or greater was lower in EP than in YP. Although
our study may have involved some degree of selection
Table 3 Types of postoperative chemotherapy
Age <75 years Age ≥75 y p value
n 115 21
Single agent 71 15 <0.01







UFT 5-fluorouracil, oxaliplatin, FOLFOX 5-fluorouracil, and folinic acid, SOX S-1
and oxaliplatin, XELOX capecitabine plus oxaliplatin
Table 4 Side effects and incidence of discontinuation of
therapy in patients who received adjuvant chemotherapy
Age <75 years Age >75 years
Single Combination Single Combination





19 (43.1 %) 0 (0 %) 2 (33.3 %)
Signs and symptoms
Neutropenia 3 9 0 2
Anorexia 3 3 0 0
Diarrhea 3 2 0 0
Pneumonia 0 1 0 0
Anaphylaxis 0 1 0 0
General fatigue 0 1 0 0
Perforation 0 1 0 0
Acute
leukoencephalopathy
0 1 0 0
Liver dysfunction 1 0 0 0
Hand-foot
syndrome
1 0 0 0
Hyperbilirubinemia 2 0 0 0
Discontinuation 8 (11.3 %) 6 (13.6 %) 1
(6.7 %)
0 (0 %)
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bias, since we made deliberate choices in terms of per-
formance status, general status, and cognitive function,
particularly in EP, our results suggest that EP can safely
receive postoperative AC if the selection of therapy is
appropriate.
Steinberg and colleagues examined 1296 colorectal can-
cer patients with local invasion or positive lymph nodes
[26]. They compared groups with and without AC and
found significantly lower cancer recurrence and overall
death rates in the AC group. Other studies have likewise re-
vealed benefits in terms of disease-free survival and overall
survival from the use of postoperative AC [27–30]. In the
present study, in both YP and EP, overall survival was better
among patients who received AC than among those who
only underwent surgery (p = 0.07 and p = 0.01, respectively).
Sanoff and colleagues examined the effects of AC in 5489
colorectal cancer patients 75 years of age and older [31].
They reported that the incidence of AC administration de-
clined with patient age. They also indicated that EP could
gain survival benefits from AC (hazard ratio, 0.60; 95 % CI,
0.53–0.68), supporting the present results. Other random-
ized clinical trials have also revealed that AC offers im-
proved disease-free and overall survival in colorectal cancer
patients over 70 years of age [32–34]. About 40 % of colo-
rectal cancer patients are reportedly over 75 years old [35],
yet older patients remain underrepresented in clinical trials
of chemotherapy because of the scarcity of efficacy data
[32]. In the future, steps should be taken to ensure greater
inclusion of older patients in such clinical trials.
Chronological age reportedly does not correlate with
physiological age [36–39]. However, many older people
are not provided AC because of their advanced chrono-
logical age (Additional file 1: Table S1) [1]. Several geri-
atric assessment tools that could help predict patient
outcomes are now available [40–42]. Hurria and col-
leagues also revealed a predictive model of chemother-
apy toxicity for older patients, and application of such
tools should be considered when selecting chemother-
apies for older patients [43]. A previous report revealed
that 29 % of colorectal cancer patients older than
70 years died due to disease recurrence, while 13 % died
due to causes unrelated to recurrence [9]. These results
indicate that appropriate chemotherapy in older patients
might confer a survival benefit in terms of cancer con-
trol, and clinicians should thus not hesitate to aggres-
sively treat cancers in EP, just as in YP.
The main drawback of this study was the selection
bias, in that only patients fit for chemotherapy were ad-
ministered treatment. Thus, definition of the circum-
stances in which chemotherapy may be selected for
node-positive patients who are elderly is paramount. A
randomized controlled trial is more likely to yield an ad-
equate assessment of whether EP should be administered
AC under strict selection criteria.
Fig. 1 Disease-free survival and overall survival of stage III colorectal cancer patients. The subgroup of patients who received adjuvant
chemotherapy displayed improved survival outcomes for both younger patients (p = 0.07; a) and elderly patients (p = 0.01; b)
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Conclusions
The present findings suggest that postoperative AC
could be effective in improving overall survival following
resection of stage III colorectal cancer, not only in YP
but also in EP. AC should therefore not be withheld
from eligible EP purely on the basis of advanced age.
Additional file
Additional file 1: Table S1. Reasons for withholding adjuvant
chemotherapy. (DOC 46 kb)
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